A Study to Investigate Leramistat in Patients With IPF
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in
participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).